Skip to main content
West Pharmaceutical Services10-Q: Restructuring charge

West Pharmaceutical records $6.3 million quarterly restructuring charges across 2025 and 2024 programs

Source: Autobound Signal API · 51 signals tracked for West Pharmaceutical Services · updated

Get West Pharmaceutical Services' live signals in Claude or ChatGPT, or by API

AskWhat changed at West Pharmaceutical Services this week? Use Autobound signals for westpharma.com.

What happened

The company recorded pre-tax charges of $6.3 million for the quarter and $9.3 million year-to-date related to severance, accelerated depreciation, and legal structure optimization.

Source

SEC EDGAROct 29, 2026

Quarterly report (Form 10-Q)

West Pharmaceutical Services 10-Q for Quarter ended Sep 30, 2026

Filing excerpt

During the three and nine months ended September 30, 2026, the Company recorded pre-tax charges of $6.3 million and $9.3 million, respectively, related to our two existing restructuring programs: (i) $5.8 million and $7.7 million, respectively, within other expense (income), related to severance and retention benefit charges and the acceleration of depreciation and lease costs in connection with the Company's January 2025 restructuring plan and (ii) $0.5 million and $1.6 million, respectively, within selling, general and administrative expenses, for professional services relating to our 2024 plan to optimize the legal structure of the Company and its subsidiaries.

sec.gov/Archives/edgar/data/105770/000010577026000121/wst-20260930.htmRead the full source

Other signals in this filing (3)

Extracted by Autobound

From the Signal API record
Signal
10-Q: Restructuring charge

What this signalsFilings often name leadership changes, deals and spending plans.

Period
Quarter ended Sep 30, 2026
Fiscal year end
09/30
Filed
Oct 29, 2026

More 10-Q signals at other companies

The full record

From the Signal API record

Numbers

Dollar figure
$6.3M (pre-tax restructuring charges for the three months ended September 30, 2026)

Details

CIK
105770
Accession number
0000105770-26-000121
Timeframe
Current quarter
Quarter
Q3
Filing year
2026
Period end date
Sep 30, 2026
Why it matters
Vendor review likely
Signal category
Financial

Extraction

Confidence
High
Relevance
75%
Sentiment
Negative
Detected
Nov 3, 2026
signal_type
sec-10q
signal_subtype
restructuringCharge

Use this data

Get every 10-Q signal for West Pharmaceutical Services and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at West Pharmaceutical Services this week?”

  2. Send it to your own tools

    The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/0a861017-74c8-4fa4-8c1e-56112d57e90f returns this record as JSON. POST /v1/companies/enrich returns every signal for westpharma.com.

{
  "signal_id": "0a861017-74c8-4fa4-8c1e-56112d57e90f",
  "signal_type": "sec-10q",
  "signal_subtype": "restructuringCharge",
  "detected_at": "2026-11-03T07:07:56.508+00:00",
  "company": {
    "name": "West Pharmaceutical Services",
    "domain": "westpharma.com"
  },
  "data": {
    "detail": "The company recorded pre-tax charges of $6.3 million for the quarter and $9.3 million year-to-date related to severance, accelerated depreciation, and legal structure optimization. This operational reshaping may indicate opportunities for restructuring advisory and operational efficiency solutions.",
    "metrics": {
      "timeframe": "current_quarter",
      "dollar_context": "pre-tax restructuring charges for the three months ended September 30, 2026",
      "dollar_millions": 6.3
    },
    "quarter": "Q3",
    "summary": "West Pharmaceutical records $6.3 million quarterly restructuring charges across 2025 and 2024 programs",
    "excerpts": "During the three and nine months ended September 30, 2026, the Company recorded pre-tax charges of $6.3 million and $9.3 million, respectively, related to our two existing restructuring programs: (i) $5.8 million and $7.7 million, respectively, within other expense (income), related to severance and retention benefit charges and the acceleration of depreciation and lease costs in connection with the Company's January 2025 restructuring plan and (ii) $0.5 million and $1.6 million, respectively, within selling, general and administrative expenses, for professional services relating to our 2024 plan to optimize the legal structure of the Company and its subsidiaries.",
    "relevance": 0.75,
    "sentiment": "negative",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/105770/000010577026000121/wst-20260930.htm",
    "filing_date": "2026-10-29",
    "filing_year": 2026,
    "fiscal_year": 2026,
    "fiscal_year_end": "09/30",
    "period_end_date": "2026-09-30",
    "sales_relevance": "Vendor review likely",
    "signal_category": "financial"
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.